NCT06233058View on ClinicalTrials.gov

Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

April 29, 2024

Study Completion Date

May 27, 2024

Conditions
Healthy Subjects
Interventions
DRUG

Drospirenone+ Ethinyl Estradiol Tablets-Test product

Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Umeda Company Limited, Thailand

DRUG

Drospirenone+ Ethinyl Estradiol Tablets-Reference product

Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Manufactured by: Bayer AG, Berlin, Germany

All Listed Sponsors
lead

Bio-innova Co., Ltd

INDUSTRY